DUBLIN--(BUSINESS WIRE)--The "Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.
Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Female Hypoactive Sexual Desire Disorder (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Hypoactive Sexual Desire Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Discovery stages are 1, 6 and 1 respectively.
Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Female Hypoactive Sexual Desire Disorder - Overview
- Female Hypoactive Sexual Desire Disorder - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Female Hypoactive Sexual Desire Disorder - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Female Hypoactive Sexual Desire Disorder - Companies Involved in Therapeutics Development
- Emotional Brain BV
- GlaxoSmithKline Plc
- Palatin Technologies Inc
- Pivot Pharmaceuticals Inc
- Strategic Science & Technologies LLC
For more information about this report visit https://www.researchandmarkets.com/research/p434gr/female_hypoactive?w=4
